Exact Sciences Stock Forecast for 2023 - 2025 - 2030
Updated on 03/29/2024
Exact Sciences Stock Forecast and Price Target
In recent months, seven notable analysts have provided yearlong price targets for Exact Sciences, with the average target coming in at $88.00. If it were to be achieved, this would result in a potential upside of approximately 44.98 percent from the most recent closing price in March, 2024. The high end is $115.00, and the low is $66.00. If you are not interested in EXAS stock, you may be interested in its competitors.
44.98% Upside
Exact Sciences Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Exact Sciences's Price has grown by 100.00%, rising from $0.00 to $0.00. For next year, analysts predict Fair Value of $65.84, which would mean an increase of 100.00%. Over the next seven years, experts predict that Exact Sciences's Fair Value will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF242.00 | Buy/Sell | CHF307.83 | 11.57% |
NOVN Stock Forecast | Novartis | Outperform |
10
|
CHF88.80 | Buy/Sell | CHF105.00 | 23.95% |
A Stock Forecast | Agilent Technologies | Outperform |
10
|
$147.29 | Buy/Sell | $138.82 | 1.84% |
ILMN Stock Forecast | Illumina | Outperform |
16
|
$139.06 | Buy/Sell | $159.28 | 7.87% |
LH Stock Forecast | Laboratory Corp of America Hol... | Outperform |
11
|
$218.53 | Buy/Sell | $241.28 | 11.20% |
Exact Sciences Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Exact Sciences's Revenue has grown by 67.61%, rising from $1.49B to $2.50B. For next year, analysts predict Revenue of $2.61B, which would mean an increase of 4.28%. Over the next seven years, experts predict that Exact Sciences's Revenue will grow at a rate of 128.56%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
HOLX Stock Forecast | Hologic | Outperform |
8
|
$76.33 | Buy/Sell | $81.06 | 7.56% |
DGX Stock Forecast | Quest Diagnostics | Outperform |
10
|
$129.43 | Buy/Sell | $141.17 | 9.94% |
ERF Stock Forecast | Eurofins Scientific | Hold |
18
|
57.08€ | Buy/Sell | 0.00€ | 3.89% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
NTRA Stock Forecast | Natera | Outperform |
7
|
$89.28 | Buy/Sell | $74.41 | 6.41% |
QGEN Stock Forecast | QIAGEN N.V. | Outperform |
15
|
$45.02 | Buy/Sell | $0.00 | 11.57% |
BIO Stock Forecast | Bio-Rad Laboratories Inc | Buy |
16
|
$344.25 | Buy/Sell | $536.80 | 26.86% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
SHL Stock Forecast | Sonic Healthcare | Hold |
18
|
$28.47 | Buy/Sell | $34.12 | 8.89% |
TXG Stock Forecast | 10x Genomics | Outperform |
6
|
$40.34 | Buy/Sell | $58.14 | 48.74% |
TWST Stock Forecast | Twist Bioscience | Outperform |
4
|
$36.86 | Buy/Sell | $34.00 | 16.66% |
Exact Sciences EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Exact Sciences's EBITDA has gone down from $-418.66M to $-122.23M – a 70.80% drop. In the next year, 6 analysts estimate that Exact Sciences's EBITDA will decrease by 246.26%, reaching $178.77M. According to professional forecasts, in 2030, Exact Sciences's EBITDA will decrease by 1244.77%, reaching $1.40B.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
GH Stock Forecast | Guardant Health | Buy |
6
|
$18.99 | Buy/Sell | $43.00 | 136.97% |
SDGR Stock Forecast | Schrödinger | Outperform |
6
|
$26.54 | Buy/Sell | $44.22 | 41.30% |
MYGN Stock Forecast | Myriad Genetics | Hold |
6
|
$22.58 | Buy/Sell | $22.08 | 10.72% |
Exact Sciences EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Exact Sciences's EBIT has fallen from $-582.02M to $-214.39M – a 63.16% decrease. In the next year, analysts believe that EBIT will reach $-297.87M – an increase of 38.94%. Professionals believe that By 2030, Exact Sciences's EBIT will fall to $1.22B – a 670.36% decrease from its current value.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
NEO Stock Forecast | NeoGenomics | Outperform |
8
|
$15.93 | Buy/Sell | $20.09 | 25.55% |
VCYT Stock Forecast | Veracyte | Outperform |
11
|
$22.66 | Buy/Sell | $32.17 | 43.42% |
OPK Stock Forecast | OPKO Health | Outperform |
8
|
$1.01 | Buy/Sell | $6.70 | 296.04% |
Exact Sciences EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Exact Sciences's EPS has grown by 100.00%, rising from $-1.43 to $0.00. For next year, analysts predict EPS of $-1.30, which would mean an increase of 100.00%. Over the next seven years, experts predict that Exact Sciences's EPS will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
CYRX Stock Forecast | Cryoport | Outperform |
8
|
$16.38 | Buy/Sell | $17.61 | 3.79% |
FLGT Stock Forecast | Fulgent Genetics | Hold |
16
|
$22.91 | Buy/Sell | $31.50 | 9.12% |
LAB Stock Forecast | Standard BioTools | Buy |
11
|
$2.78 | Buy/Sell | $4.00 | 43.88% |